Ursula J Buchholz

Title: The Innovations of Ursula J Buchholz in Vaccine Development

Introduction: Ursula J Buchholz, based in Silver Spring, Maryland, is a prominent figure in the field of vaccine development. With an impressive portfolio of 31 patents, her contributions primarily focus on viral proteins and innovative vaccine strategies aimed at combatting serious respiratory infections.

Latest Patents: Among her latest innovations, Buchholz has developed significant patents related to metapneumovirus (MPV) and respiratory syncytial virus (RSV). One notable patent discloses recombinant MPV F proteins, which are stabilized in a prefusion conformation. These proteins and associated nucleic acid molecules have the potential to elicit an immune response against MPV in subjects. Moreover, her work includes a method of vaccination with a live attenuated RSV vaccine formulation, which showcases a single dose of a recombinant RSV lacking the M2-2 protein. This method has shown to induce a stronger immune response than previous candidates, while effectively limiting viral replication.

Career Highlights: Ursula has held significant roles in various organizations, primarily associated with the U.S. Department of Health and Human Services. Her work embodies a dedication to advancing public health through innovative vaccination strategies.

Collaborations: Throughout her career, Buchholz has collaborated with notable colleagues, including Peter L Collins and Brian R Murphy. These collaborations have enriched her research and contributed to the development of effective vaccine formulations.

Conclusion: Ursula J Buchholz's work stands as a testament to innovation in the field of virology and vaccine development. Her patents not only contribute to scientific knowledge but also pave the way for effective prevention strategies against respiratory infections, ultimately aiming to improve public health outcomes.